A5079494402- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Bone health and treatments
- Cancer Mechanisms and Therapy
Affiliated Hospital of Hebei University
2016-2025
Peking Union Medical College Hospital
2022
Chinese Academy of Medical Sciences & Peking Union Medical College
2022
BeiGene (China)
2022
Hebei Medical University
2020-2021
Hebei University
2009-2021
Genistein is a soybean isoflavone; in its aglycone it has various biological activities. Animal experiments, clinical studies and epidemiological investigations suggest that genistein preventative curative functions for number of diseases, particularly cancer. The present study explored the potential anti-cancer effect by observing role inhibiting A549 human lung cancer cell proliferation investigating possible mechanism. cells were exposed to concentrations (0, 10, 25, 50, 100 200 µM;...
Background Accumulating evidence supports the hypothesis that cancer stem cells (CSCs) are essential for initiation, metastasis and drug resistance. However, functional association of gastric CSC markers with stemness epithelial-mesenchymal transition (EMT) signature genes is unclear. Methods qPCR was performed to measure expression profiles EMT their putative in tissues, cell lines sphere cells. Western blot analysis used confirm results transcript analysis. Cell proliferation, migration,...
Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small-scale study. Here, we conducted multicenter, randomized, phase 3 study to compare safety cisplatin plus (LP) versus gemcitabine (GP) as first-line treatment or metastatic LSCC.Patients enrolled were aged between 18 75 years, had (clinical stage IIIB, ineligible for concurrent chemoradiation surgery) (Stage IV)...
Emerging evidence indicates that microRNAs are involved in the development and progression of gastric cancer (GC), functioning as tumor suppressors or oncogenes. The aim current study was to explore potential mechanism microRNA-425-5p (miR-425-5p) GC. Using reverse transcription quantitative polymerase chain reaction, miR-425-5p expression detected GC cell lines (SGC-7901, MKN-28, MKN-45, BGC-823 AGS) GES-1 line. Cell proliferation, soft agar colony formation, flow cytometry, haptotactic...
Abstract Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients metastatic colorectal cancer (mCRC): a real-world study. Methods The data who received regorafenib-containing regimen as third later line treatment at ten hospitals from Aug 2017 to Jun 2020 were retrospectively analyzed, including dosing details, survival well adverse events. Survival analysis was further performed for...
Abstract Background The development of immune checkpoint inhibitors has made a significant breakthrough in the treatment non‐small‐cell lung cancer (NSCLC). However, there remains huge unmet clinical need for patients with acquired resistance after initial response. Methods This study evaluated combination IBI310 (an anti‐cytotoxic T lymphocyte‐associated antigen‐4 [CTLA‐4] antibody) and sintilimab anti‐programmed death 1 [PD‐1]) NSCLC who have previously been treated anti‐PD‐1/ligand (L)1...
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Triptolide is used in traditional Chinese medicine. It has the advantages of a unique mechanism action, wide antitumor spectrum, multiple targets, multi-channel effects and low toxicity. The current study was conducted to evaluate whether potential anticancer triptolide reduces proliferation enhances apoptosis human non‑small cell lung cancer (NSCLC) cells, assess underlying mechanisms. In PC‑9 treatment with reduced increased caspase‑3 9 activity. miR‑21 expression enhanced phosphatase...
The underlying mechanisms of inhibitory effects induced by tetramethylpyrazine (TMP) on angiogenesis and tumor growth lung cancer were investigated. In vitro cell proliferation, migration, tube formation human microvascular endothelial cells (HMEC-1) evaluated a 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide (MTT), wound healing, Transwell, Matrigel assays. expression BMP/Smad/Id-1 signals was detected RT-PCR western blotting. an A549 xenograft model, TMP (40 80 mg/kg/day)...
Breast cancer is one of the most prevalent types among women that leads to millions deaths worldwide every year. The mechanisms breast pathogenesis remain unclear. It has been reported aberrant expression miR-519, associated with development; however, effects miR-519 on cell proliferation unknown. Therefore, present study aimed determine whether could regulate proliferation. A total 20 pairs primary and adjacent normal tissues were collected from patients cancer. level was determined by...
Abstract Purpose: Our primary purpose is to explore safety and efficacy of high-dose icotinib in comparison with routine-dose patients non–small cell lung cancer (NSCLC) harboring 21-L858R mutation. Patients Methods: treatment-naïve, EGFR-mutant (21-L858R or exon 19 deletion at 2:1) NSCLC were enrolled. mutation randomized receive (125 mg, thrice daily; L858R-RD) (250 L858R-HD), whereas received only (19-Del-RD) until progression, death, unacceptable toxicity. The endpoint was median...
It is widely known that some specific microRNAs can regulate the expressions of genes in gastric cancer cells at post-transcriptional level. Previous studies have identified miRNA-4766-5p was involved tumor cell proliferation and be an independent prognostic indicator for malignant pleural mesothelioma. However, mechanism underlying via pathway remains to blank.We investigated expression miR-4766-5p tissues through qRT-PCR. We used RNAi change lines, AGS MKN45. Quantitative real-time...
Apatinib has been proved to be effective and well tolerated among patients in phase II III studies. Here, we evaluated the safety effectiveness of apatinib advanced gastric cancer a real-world setting.This study enrolled who had progressed or relapsed despite systemic chemotherapy. The primary outcome was secondary outcomes included overall survival (OS) progression-free (PFS).A total 337 were included. In total, 62 (18.4%), 102 (30.3%), 173 (51.3%) received first, second, third higher line...
We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) this phase 3, randomized, double-blind study.Patients untreated NSCLC were randomized (1:1 ratio) to receive either combination paclitaxel/carboplatin. Patients non-progressive disease continued maintenance single-agent until progression, intolerable toxicity. The primary endpoint was 12-week...
Abstract Purpose To evaluate the safety, tolerability, and preliminary efficacy of multiple doses pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients. Methods According to “3 + 3” dose‐escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m 2 once every 3 weeks four cycles. Progression‐free survival (PFS), overall (OS), median progression‐free (mPFS), (mOS) were evaluated. The Kaplan–Meier method was used...
4592 Background: Advanced HCC is a deadly disease with few systemic therapeutic options. VEGF blockade potentiates the effect of PD-1 inhibition by opposing immunosuppressive effects VEGF-A (increased DC maturation, enhanced T-cell infiltration, reduced MDSCs and Tregs in tumors). A sBLA has been submitted for an anti-PD-L1 + anti-VEGF combination as 1L treatment advanced HCC. Penpulimab novel humanized anti-PD-1 IgG1 antibody complete removal Fc receptor mediated effect, featuring slow...